Immunome Inc (IMNM) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access IMNM Annual Balance Sheets →
Balance sheet patterns shown here provide context for understanding Immunome Inc's financial stability and long-term positioning.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent217.71
Available-for-sale Securities, Debt Securities, Current MA302.29
Cash & Short-term Investments519.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current18.45
Total Current Assets538.45
Equipment/Property/Plant Net17.36
Other Assets, Noncurrent9.58
Restricted Cash Noncurrent0.21
Total Assets565.38
Liabilities
Accounts Payable, Current AC6.00
Accrued Liabilities And Other Liabilities6.17
Other Liabilities, Current23.55
Total Current Liabilities35.71
Total Long-term Debt0.00
Other liabilities, Noncurrent4.59
OperatingLeaseLiabilityNoncurrent3.69
Contract With Customer Liability Current-
Contract With Customer Liability Noncurrent-
Total Liabilities40.30
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock1,380.54
Retained Earnings / Accumulated Deficit-855.13
Accumulated Other Comprehensive Income-0.33
Other Equity-0.33
Common Stockholder's Equity525.08
Total Stockholder's Equity525.08
Liabilities & Stockholder's Equity565.38
4 historic quarters locked

Sign in to unlock the full Immunome Inc balance sheet history.

About Immunome Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-344636

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.